Death of a volunteer

November 12, 2001

In June 2001 a 24-year-old woman who had been paid US$365 to participate in a research project died of pulmonary complications after receiving a drug at the Johns Hopkins Asthma and Allergy Center. Dr. Richard Ian Ogilvie asks whether the same thing could occur in Canada, and concludes that a similar event is possible. He says research ethics boards, which must approve research protocols, should review the consent process. (The woman was never told that the drug was not approved for clinical use.) He also says the coercion of volunteers must end.
-end-
p. 1335 The death of a volunteer research subject: lessons to be learned -- R.I. Ogilvie

Canadian Medical Association Journal

Related Pulmonary Complications Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

Pulmonary fibrosis treatment shows proof of principle
A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

New technical approach can enhance diagnosis of pulmonary hypertension
The management and prognosis of pulmonary hypertension heavily relies on whether the pathology is localized in pulmonary arteries or veins.

Pulmonary embolism and COVID-19
Researchers at Henry Ford Health System in Detroit say early diagnosis of a life-threatening blood clot in the lungs led to swifter treatment intervention in COVID-19 patients.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

Rates of pulmonary complications drastically reduced with newer drug
A team of researchers at Michigan Medicine found the drug sugammadex was associated with significantly reduced rates of pulmonary complications following surgery.

Specific gut bacteria may be associated with pulmonary arterial hypertension
Researchers have found a specific bacterial profile in the gut of people with pulmonary arterial hypertension, a chronic and progressive disease that causes constriction of arteries in the lungs.

Advancing an oral drug for pulmonary arterial hypertension
With a protein drug grown in the leaves of lettuce plants, the University of Pennsylvania's Henry Daniell and colleagues hope to provide new treatment options for patients with pulmonary arterial hypertension, a rare but deadly disease.

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

Better way to interpret blood tests to diagnose pulmonary embolism
A study led by Hamilton researchers has found a new way to interpret blood test results in patients who are investigated for blood clots in their lungs, a condition known as pulmonary embolism.

Read More: Pulmonary Complications News and Pulmonary Complications Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.